Another pharma firm asks court to stop EMA from releasing data
This article was originally published in SRA
The European Medicines Agency is facing yet another legal challenge in relation to its access to documents policy.
You may also be interested in...
The EU General Court has dismissed three cases by pharmaceutical companies that wanted to prevent the European Medicines Agency from disclosing certain data about their marketed medicines on the grounds that it would harm their commercial interests. Firms now have a clearer idea of the standards they will need to meet to claim their information is commercially confidential.
The European Medicines Agency is keen to highlight its landmark policy on proactive publication of clinical data but it’s aware of the challenges involved in this and other transparency initiatives.
As the European Medicines Agency's policy on access to documents faces yet another legal challenge, the European Confederation of Pharmaceutical Entrepreneurs is hoping the verdict will demystify what constitutes commercially confidential information in a marketing authorization application.